EGFR and nasopharyngeal carcinoma: Our research in the well-balanced cohort found that when compared to concurrent anti-EGFR therapy alone, adding concurrent chemotherapy significantly improved the PFS and OS of stage II-IVb NPC patients (P=0.039 for PFS and P=0.012 for OS).